{"disease":{"id":"locally-advanced-or-metastatic-breast-cancer","name":"locally advanced or metastatic breast cancer"},"drugs":{"marketed":[{"drug_id":"talzenna","indication_name":"BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"Talazoparib Tosylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PARP1 and PARP2 enzymes","drug_class":"PARP inhibitor","quality_score":75,"revenue":"182","mechanism":"PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy, in combination with inavolisib and fulvestrant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"chembl-chembl4650215","indication_name":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"INAVOLISIB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04546009","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":992,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05296798","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":922,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04862663","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":895,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04305496","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05172518","title":"Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":512,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06680921","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Jiangsu Simcere Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07461454","title":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":376,"lead_sponsor_name":"MediLink Therapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT05744687","title":"Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":374,"lead_sponsor_name":"Shanghai Pharmaceuticals Holding Co., Ltd","has_results":false},{"nct_id":"NCT05306340","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":373,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT03027245","title":"Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy","phase":"","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Eisai GmbH","has_results":false},{"nct_id":"NCT05430399","title":"Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":349,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03437083","title":"A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants","phase":"","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"Eisai Korea Inc.","has_results":false},{"nct_id":"NCT04606446","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04802759","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":316,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04576455","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":303,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05054751","title":"GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Genor Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT05860465","title":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":254,"lead_sponsor_name":"Shanghai Pharmaceuticals Holding Co., Ltd","has_results":false},{"nct_id":"NCT06846437","title":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":228,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT02514681","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Japan Breast Cancer Research Group","has_results":false},{"nct_id":"NCT06439771","title":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"MediLink Therapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT03584009","title":"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06764186","title":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":101,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03781063","title":"Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Sermonix Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT05403333","title":"Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":61,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07182721","title":"SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05458674","title":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Criterium, Inc.","has_results":false},{"nct_id":"NCT07294430","title":"Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"UNICANCER","has_results":false}],"total":27},"guidelines":[],"source":"Drug Landscape verified database"}